Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/FER_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/FER_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/FER_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/FER_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/FER_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/FER_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/FER_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/FER_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/FER_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/FER_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003249620 | Skin | AK | response to lipopolysaccharide | 55/1910 | 343/18723 | 4.79e-04 | 4.44e-03 | 55 |
GO:00716348 | Skin | AK | regulation of transforming growth factor beta production | 12/1910 | 41/18723 | 5.77e-04 | 5.13e-03 | 12 |
GO:190382810 | Skin | AK | negative regulation of cellular protein localization | 24/1910 | 117/18723 | 6.54e-04 | 5.64e-03 | 24 |
GO:00336276 | Skin | AK | cell adhesion mediated by integrin | 17/1910 | 72/18723 | 7.51e-04 | 6.32e-03 | 17 |
GO:000717910 | Skin | AK | transforming growth factor beta receptor signaling pathway | 35/1910 | 198/18723 | 8.69e-04 | 7.17e-03 | 35 |
GO:00510909 | Skin | AK | regulation of DNA-binding transcription factor activity | 66/1910 | 440/18723 | 8.99e-04 | 7.40e-03 | 66 |
GO:00716047 | Skin | AK | transforming growth factor beta production | 12/1910 | 43/18723 | 9.25e-04 | 7.53e-03 | 12 |
GO:000223720 | Skin | AK | response to molecule of bacterial origin | 56/1910 | 363/18723 | 1.10e-03 | 8.60e-03 | 56 |
GO:012003219 | Skin | AK | regulation of plasma membrane bounded cell projection assembly | 33/1910 | 186/18723 | 1.13e-03 | 8.75e-03 | 33 |
GO:006049119 | Skin | AK | regulation of cell projection assembly | 33/1910 | 188/18723 | 1.36e-03 | 1.01e-02 | 33 |
GO:000828610 | Skin | AK | insulin receptor signaling pathway | 23/1910 | 116/18723 | 1.36e-03 | 1.01e-02 | 23 |
GO:003286819 | Skin | AK | response to insulin | 43/1910 | 264/18723 | 1.37e-03 | 1.02e-02 | 43 |
GO:003227326 | Skin | AK | positive regulation of protein polymerization | 26/1910 | 138/18723 | 1.50e-03 | 1.08e-02 | 26 |
GO:009758117 | Skin | AK | lamellipodium organization | 19/1910 | 90/18723 | 1.61e-03 | 1.15e-02 | 19 |
GO:003461425 | Skin | AK | cellular response to reactive oxygen species | 28/1910 | 155/18723 | 1.95e-03 | 1.32e-02 | 28 |
GO:000181917 | Skin | AK | positive regulation of cytokine production | 67/1910 | 467/18723 | 2.59e-03 | 1.67e-02 | 67 |
GO:003444624 | Skin | AK | substrate adhesion-dependent cell spreading | 21/1910 | 108/18723 | 2.75e-03 | 1.75e-02 | 21 |
GO:00510927 | Skin | AK | positive regulation of NF-kappaB transcription factor activity | 27/1910 | 152/18723 | 2.97e-03 | 1.87e-02 | 27 |
GO:0042634 | Skin | AK | regulation of hair cycle | 8/1910 | 26/18723 | 3.36e-03 | 2.05e-02 | 8 |
GO:00480088 | Skin | AK | platelet-derived growth factor receptor signaling pathway | 13/1910 | 56/18723 | 3.55e-03 | 2.15e-02 | 13 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FER | SNV | Missense_Mutation | rs763459582 | c.556G>A | p.Val186Ile | p.V186I | P16591 | protein_coding | deleterious(0.05) | probably_damaging(0.97) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FER | SNV | Missense_Mutation | | c.2126N>G | p.Glu709Gly | p.E709G | P16591 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
FER | SNV | Missense_Mutation | rs533871351 | c.362N>C | p.Ile121Thr | p.I121T | P16591 | protein_coding | deleterious(0.02) | benign(0.046) | TCGA-BH-A18V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FER | SNV | Missense_Mutation | novel | c.1598N>A | p.Thr533Lys | p.T533K | P16591 | protein_coding | tolerated(0.97) | benign(0.045) | TCGA-BH-A42T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FER | SNV | Missense_Mutation | | c.281N>G | p.Ser94Cys | p.S94C | P16591 | protein_coding | deleterious(0.01) | possibly_damaging(0.554) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FER | SNV | Missense_Mutation | novel | c.1484N>A | p.Ser495Tyr | p.S495Y | P16591 | protein_coding | deleterious(0) | possibly_damaging(0.722) | TCGA-EW-A6SA-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
FER | SNV | Missense_Mutation | | c.2207G>A | p.Arg736Lys | p.R736K | P16591 | protein_coding | tolerated(0.19) | probably_damaging(0.97) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
FER | deletion | Frame_Shift_Del | novel | c.1357delN | p.Lys453SerfsTer16 | p.K453Sfs*16 | P16591 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
FER | SNV | Missense_Mutation | novel | c.2332C>T | p.Arg778Trp | p.R778W | P16591 | protein_coding | deleterious(0) | benign(0.267) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
FER | SNV | Missense_Mutation | | c.2207N>C | p.Arg736Thr | p.R736T | P16591 | protein_coding | tolerated(0.07) | probably_damaging(0.993) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | inhibitor | 328083505 | | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | ALISERTIB | ALISERTIB | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | inhibitor | 249565817 | | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | TAMATINIB | R-406 | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | CENISERTIB | CENISERTIB | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | CYC-116 | CYC-116 | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | LINIFANIB | LINIFANIB | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | ENTRECTINIB | ENTRECTINIB | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | CEDIRANIB | CEDIRANIB | |